An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. And retail traders should know. We noticed this today when the trades showed up on publicly ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other most ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other most oversold healthcare stocks to buy now. Healthcare costs and spending have been ...

On day one at Vertex, he knew that he wanted to work on BCL11A. Over the next nine years, Altshuler oversaw further research and development of the experimental therapy through a plethora of ...

James R. Kasinger, the General Counsel and Secretary of CRISPR Therapeutics AG (NASDAQ:CRSP), recently executed a series of transactions involving the company's common shares. According to a Form ...

This is the first in a se­ries of sto­ries from End­points News that looks at the fu­ture of CRISPR and its im­pact on pa­tients, sci­ence … ...